Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mydecine Innovations Group Inc
(OP:
MYCOF
)
0.0075
+0.0020 (+36.36%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mydecine Innovations Group Inc
< Previous
1
2
3
4
Next >
Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience
February 15, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Marks a Major Step in Seamless Phase 2/3 Smoking Cessation Clinical Trial; Partners with Combat Stress to Treat PTSD among Veterans
February 08, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program
February 08, 2022
Via
Investor Brand Network
Topics
Supply Chain
Exposures
Supply Chain
Mydecine Innovations Group develops novel compounds for treating mental health
February 07, 2022
Via
AB Newswire
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale
February 03, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Clinical LOI to Further Use of Psychedelic Therapeutics in Treating Mental Illnesses
February 02, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation
February 01, 2022
Via
Investor Brand Network
Exposures
Product Safety
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market
January 31, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices
January 24, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Partnership to Treat PTSD in Veterans
January 24, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) to Launch Specialized Psychedelic Program in Canada
January 24, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies
January 18, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy
January 13, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast
January 11, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program
January 10, 2022
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Engages JBN Partners LLC, Completes Target-Based Model for AI-Driven Drug Discovery Program
January 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NF.F) Featured on ‘Gamechangers LIVE’
January 06, 2022
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation
January 05, 2022
Via
Investor Brand Network
Topics
Death
Exposures
Death
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Expanding Robust Portfolio of Novel Compounds
December 30, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), Maya to Collaborate in Development of Novel DTx Platform
December 22, 2021
Via
Investor Brand Network
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine
December 20, 2021
Via
Investor Brand Network
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment
December 20, 2021
Via
Investor Brand Network
Mind Medicine (NASDAQ: MNMD) (NEO: MMED) to Study Effect of Time on LSD Microdosing
December 17, 2021
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin
December 10, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies
December 16, 2021
Palm Beach, FL –December 16, 2021 – FinancialNewsMedia.com News Commentary – Drugs like ketamine and psilocybin — the active ingredient in magic mushrooms — are showing real promise in addressing...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Financing to Provide Runway for Key Milestones
December 09, 2021
Via
Investor Brand Network
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Finishing Up Significant 2021 Calendar Year
December 07, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Patent Application Covering Multiple Families of Psilocin Analogs
December 06, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment
December 01, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Releases Q3 Update, Details JHU Five-Year Research Agreement
December 01, 2021
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.